Yan Liu1, Chung-Chou H Chang, Gary M Marsh, Felicia Wu. 1. University of Pittsburgh, Graduate School of Public Health, Department of Environmental and Occupational Health, Pittsburgh, PA 15219, USA.
Abstract
BACKGROUND: Over 4 billion people worldwide are exposed to dietary aflatoxins, which cause liver cancer (hepatocellular carcinoma, HCC) in humans. However, the population attributable risk (PAR) of aflatoxin-related HCC remains unclear. METHODS: In our systematic review and meta-analysis of epidemiological studies, summary odds ratios (ORs) of aflatoxin-related HCC with 95% confidence intervals were calculated in HBV+ and HBV- individuals, as well as the general population. We calculated the PAR of aflatoxin-related HCC for each study as well as the combined studies, accounting for HBV status. RESULTS: Seventeen studies with 1680 HCC cases and 3052 controls were identified from 479 articles. All eligible studies were conducted in China, Taiwan, or sub-Saharan Africa. The PAR of aflatoxin-related HCC was estimated at 17% (14-19%) overall, and higher in HBV+ (21%) than HBV- (8.8%) populations. If the one study that contributed most to heterogeneity in the analysis is excluded, the summarised OR of HCC with 95% CI is 73.0 (36.0-148.3) from the combined effects of aflatoxin and HBV, 11.3 (6.75-18.9) from HBV only and 6.37 (3.74-10.86) from aflatoxin only. The PAR of aflatoxin-related HCC increases to 23% (21-24%). The PAR has decreased over time in certain Taiwanese and Chinese populations. CONCLUSIONS: In high exposure areas, aflatoxin multiplicatively interacts with HBV to induce HCC; reducing aflatoxin exposure to non-detectable levels could reduce HCC cases in high-risk areas by about 23%. The decreasing PAR of aflatoxin-related HCC reflects the benefits of public health interventions to reduce aflatoxin and HBV.
BACKGROUND: Over 4 billion people worldwide are exposed to dietary aflatoxins, which cause liver cancer (hepatocellular carcinoma, HCC) in humans. However, the population attributable risk (PAR) of aflatoxin-related HCC remains unclear. METHODS: In our systematic review and meta-analysis of epidemiological studies, summary odds ratios (ORs) of aflatoxin-related HCC with 95% confidence intervals were calculated in HBV+ and HBV- individuals, as well as the general population. We calculated the PAR of aflatoxin-related HCC for each study as well as the combined studies, accounting for HBV status. RESULTS: Seventeen studies with 1680 HCC cases and 3052 controls were identified from 479 articles. All eligible studies were conducted in China, Taiwan, or sub-Saharan Africa. The PAR of aflatoxin-related HCC was estimated at 17% (14-19%) overall, and higher in HBV+ (21%) than HBV- (8.8%) populations. If the one study that contributed most to heterogeneity in the analysis is excluded, the summarised OR of HCC with 95% CI is 73.0 (36.0-148.3) from the combined effects of aflatoxin and HBV, 11.3 (6.75-18.9) from HBV only and 6.37 (3.74-10.86) from aflatoxin only. The PAR of aflatoxin-related HCC increases to 23% (21-24%). The PAR has decreased over time in certain Taiwanese and Chinese populations. CONCLUSIONS: In high exposure areas, aflatoxin multiplicatively interacts with HBV to induce HCC; reducing aflatoxin exposure to non-detectable levels could reduce HCC cases in high-risk areas by about 23%. The decreasing PAR of aflatoxin-related HCC reflects the benefits of public health interventions to reduce aflatoxin and HBV.
Authors: G D Kirk; A M Camus-Randon; M Mendy; J J Goedert; P Merle; C Trépo; C Bréchot; P Hainaut; R Montesano Journal: J Natl Cancer Inst Date: 2000-01-19 Impact factor: 13.506
Authors: C J Chen; M W Yu; Y F Liaw; L W Wang; S Chiamprasert; F Matin; A Hirvonen; D A Bell; R M Santella Journal: Am J Hum Genet Date: 1996-07 Impact factor: 11.025
Authors: R E Omer; L Verhoef; P Van't Veer; M O Idris; A M Kadaru; E Kampman; A Bunschoten; F J Kok Journal: Cancer Causes Control Date: 2001-01 Impact factor: 2.506
Authors: Ragaa E Omer; Anneleen Kuijsten; Abdelgadir M Y Kadaru; Frans J Kok; Mohammed O Idris; Ibrahim M El Khidir; Pieter van 't Veer Journal: Nutr Cancer Date: 2004 Impact factor: 2.900
Authors: R K Ross; J M Yuan; M C Yu; G N Wogan; G S Qian; J T Tu; J D Groopman; Y T Gao; B E Henderson Journal: Lancet Date: 1992-04-18 Impact factor: 79.321
Authors: G S Qian; R K Ross; M C Yu; J M Yuan; Y T Gao; B E Henderson; G N Wogan; J D Groopman Journal: Cancer Epidemiol Biomarkers Prev Date: 1994 Jan-Feb Impact factor: 4.254
Authors: D Githang'a; R N Wangia; M W Mureithi; S O Wandiga; C Mutegi; B Ogutu; A Agweyu; J-S Wang; O Anzala Journal: Curr Probl Pediatr Adolesc Health Care Date: 2019-05-16